KMT2B-mediated tumorigenesis in cervical cancer is conditioned by inducing angiogenesis and modulating the epithelial growth factor pathway, hinting that targeting epithelial growth factor receptors could boost therapeutic efficacy in cervical cancer patients exhibiting high KMT2B expression [127]. This evidence concerns the gene KMT2B and cervical carcinoma.